Create issue ticket

52 Possible Causes for B43 genistein, immunoconjugate

Show results in: 日本語

  • Chelating Agent

    Labelling of the immunoconjugate with copper-64 was achieved in high radiochemical yields after 45 min at 37 C, and the radiochemical purity of each 64 Cu-BFC-Fab-trastuzumab[] None of the patients who received DOTA-coupled antibody had detectable antibodies against the macrocycle before immunoconjugate administration.[] RESULTS: When radioimmunoconjugates were labelled with (99m)Tc, the specific activity of immunoconjugates was 20-30 mCi/mg of protein and their immunoreactivity exceeded 80%[]

    Missing: B43 genistein
  • Cutaneous T-Cell Lymphoma

    […] pharmacology Immunoconjugates/therapeutic use* Ki-1 Antigen/metabolism* Lymphoma, T-Cell, Cutaneous/drug therapy* Lymphoma, T-Cell, Cutaneous/metabolism* Lymphoma, T-Cell[] , Cutaneous/mortality Lymphoma, T-Cell, Cutaneous/pathology Treatment Outcome Substances Antineoplastic Agents, Immunological Immunoconjugates Ki-1 Antigen brentuximab vedotin[] Antineoplastic Agents, Immunological/pharmacology Antineoplastic Agents, Immunological/therapeutic use* Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Humans Immunoconjugates[]

    Missing: B43 genistein
  • T-Cell Prolymphocytic Leukemia

    […] pharmacology Immunoconjugates/therapeutic use Ki-1 Antigen/metabolism Leukemia, Prolymphocytic, T-Cell/blood Leukemia, Prolymphocytic, T-Cell/drug therapy Leukemia, Prolymphocytic[] Drug Resistance, Neoplasm/drug effects Drug Resistance, Neoplasm/genetics* Epigenesis, Genetic*/drug effects Female Gene Expression Regulation, Leukemic/drug effects Humans Immunoconjugates[] Real-Time Polymerase Chain Reaction STAT5 Transcription Factor/genetics Skin/drug effects Skin/pathology Treatment Outcome Substances Antibodies, Monoclonal, Humanized Chromatin Immunoconjugates[]

    Missing: B43 genistein
  • Follicular Lymphoma

    Immunoconjugates Immunoconjugates are antibodies that are joined to a second molecule such as a toxin to form an antibody–drug combination.[] Future studies will help to clarify the role of newer regimens such as immunoconjugates and br -based combination therapies.[] A number of novel therapies are being examined in this setting, including monoclonal antibodies, immunoconjugates, immunomodulatory agents, and signal transduction inhibitors[]

    Missing: B43 genistein
  • Vinca Alkaloid

    The B72.3-Vinca alkaloid immunoconjugate demonstrated significant antitumor activity against LS174T xenografts, although complete regressions of established tumors were not[] Parallel therapy with equivalent doses of free DAVLB-HY or a non-antigen-binding immunoconjugate did not significantly increase the survival of the animals.[] Significant increases in survival (i.e. 3-9-fold over untreated control animals) were observed with all the immunoconjugates tested but with varying potency and efficacy dependent[]

    Missing: B43 genistein
  • Encephalomyelitis

    […] chemistry Immunoconjugates/genetics Immunoconjugates/pharmacology* Injections, Subcutaneous Mice Peptides/chemical synthesis Peptides/immunology Protein Array Analysis/methods[] * Receptors, Antigen, B-Cell/antagonists & inhibitors* Receptors, Antigen, B-Cell/genetics Receptors, Antigen, B-Cell/immunology Substances Alkynes Autoantigens Azides Immunoconjugates[] Autoimmune, Experimental/pathology Encephalomyelitis, Autoimmune, Experimental/therapy* Gene Expression Regulation Humans Hyaluronic Acid/chemistry Immune Tolerance/drug effects Immunoconjugates[]

    Missing: B43 genistein
  • Anaplastic Large Cell Lymphoma

    Oncology/standards* Neoplasm Staging Positron-Emission Tomography Surgery, Plastic/standards* Tomography, X-Ray Computed Substances Anthracyclines Antibiotics, Antineoplastic Immunoconjugates[] […] vedotin Publication type, MeSH terms, Substances Publication type Case Reports MeSH terms Adult Antineoplastic Agents/therapeutic use* Biomarkers, Tumor/analysis Humans Immunoconjugates[] Brentuximab vendotin, an antibody-drug conjugate or immunoconjugate directed to the CD30 protein, is usually reserved for refractory cases.[]

    Missing: B43 genistein
  • Drug-induced Peripheral Neuropathy

    Many patients with lymphoma who are treated with brentuximab vedotin (BV), an immunoconjugate drug, experience peripheral neuropathy (PN), though the therapy’s outcomes may[]

    Missing: B43 genistein
  • Hairy Cell Leukemia

    MANAGEMENT OF PROGRESSIVE OR REFRACTORY DISEASE: It is based on the use of BRAF inhibitors associated or not with MEK inhibitors, recombinant immunoconjugates targeting CD22[] Currently, the most promising therapeutic strategies for relapsed or refractory HCL include recombinant immunoconjugates targeting CD22 (e.g. moxetumomab pasudotox), BRAF[]

    Missing: B43 genistein
  • Endometriosis

    The immunoconjugate molecule (Icon) targets Tissue Factor, a transmembrane receptor for Factor VII/VIIa that is aberrantly expressed in the endothelium supporting ectopic[]

    Missing: B43 genistein

Further symptoms